Tamoxifen
Aromatase inhibitors compared to antiestrogens
Published in Cancer Weekly, July 5th, 2005
According to recent research from England, "AIs have been in use to treat metastatic breast cancer for over 25 years. Recently potent and specific AIs have been introduced, which, because of their low toxicity profile, are being used in the adjuvant and neoadjuvant situation and also for the prevention of breast cancer."
"The two non-steroidal AIs, anastrozole and letrozole, and the steroidal AI, exemestane, have all shown superiority to tamoxifen as first-line treatment for advanced breast cancer. Interestingly, the estrogen receptor downregulator, fulvestrant, was shown to be equivalent to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-07-05)
More Articles from Cancer Weekly
- Computed Tomography
Diagnostic imaging influenced costs of hospital care - Lung Cancer
Pharmaceutical management of patients during lung cancer chemotherapy advised - Oncology Surveys
Radiation oncology emerging as Canada's premier career choice - Palliative Care
Fear of death among young and elderly with terminal cancers in Taiwan examined - Pediatric Cancer
Change in marital relationships linked to stress of coping with child's cancer - Acute Lymphoblastic Leukemia
Multiple subclones identified in TEL-AML1 at diagnosis - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
